PMID- 18814092
OWN - NLM
STAT- MEDLINE
DCOM- 20081031
LR  - 20181201
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 133 Suppl 6
DP  - 2008 Oct
TI  - [Specific drugs for the treatment of pulmonary arterial hypertension - current 
      status].
PG  - S183-6
LID - 10.1055/s-0028-1091234 [doi]
AB  - For some years drugs of several different classes have been available in Germany 
      for the treatment of pulmonary arterial hypertension (PHT): prostanoids, 
      endothelin-receptor antagonists and phosphodiesterase inhibitors. To-date all 
      relevant studies have consistently shown improvement in the 6-minute walking test 
      (Iloprost, Treprostinil, Bosentan, Sitaxentan, Ambrisentan, Sildenafil). Results 
      have not been consistent when the end-point has been an improvement in New York 
      Heart Association (NYHA) class III or in the time to clinical worsening. Despite 
      the good safety data for all drugs approved in Germany in the treatment of PHT, 
      there are some clinically relevant interactions and significant 
      contraindications. The availability of several options demands a detailed 
      knowledge of studies to optimize safety and success in the treatment of PHT. 
      Placebo-control mortality studies are not available for ethical reasons for those 
      drugs that have been approved in Germany. But cohort analyses using historical 
      survival rates have demonstrated a impressive improvement in survival of patients 
      with PHT. Although there has been great progress in the treatment of PHT, a cure 
      of this grave disease is not yet possible.
FAU - Stahler, G
AU  - Stahler G
AD  - Medizinische Klinik I Pneumologie, Klinik Lowenstein. 
      gerd.staehler@klinik-loewenstein.de
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Spezifische Medikamente zur Behandlung der pulmonal-arteriellen Hypertonie - 
      aktueller Stand.
DEP - 20080923
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Isoxazoles)
RN  - 0 (Phenylpropionates)
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Prostaglandins)
RN  - 0 (Purines)
RN  - 0 (Pyridazines)
RN  - 0 (Sulfonamides)
RN  - 0 (Sulfones)
RN  - 0 (Thiophenes)
RN  - 0 (Vasodilator Agents)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - HW6NV07QEC (ambrisentan)
RN  - J9QH779MEM (sitaxsentan)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Bosentan
MH  - Endothelin Receptor Antagonists
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/mortality
MH  - Isoxazoles/therapeutic use
MH  - Phenylpropionates/therapeutic use
MH  - Phosphodiesterase 5 Inhibitors
MH  - Phosphodiesterase Inhibitors/therapeutic use
MH  - Piperazines/therapeutic use
MH  - Prostaglandins/therapeutic use
MH  - Purines/therapeutic use
MH  - Pyridazines/therapeutic use
MH  - Sildenafil Citrate
MH  - Sulfonamides/therapeutic use
MH  - Sulfones/therapeutic use
MH  - Survival Rate
MH  - Thiophenes/therapeutic use
MH  - Vasodilator Agents/therapeutic use
RF  - 16
EDAT- 2008/10/01 09:00
MHDA- 2008/11/01 09:00
CRDT- 2008/10/01 09:00
PHST- 2008/10/01 09:00 [pubmed]
PHST- 2008/11/01 09:00 [medline]
PHST- 2008/10/01 09:00 [entrez]
AID - 10.1055/s-0028-1091234 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2008 Oct;133 Suppl 6:S183-6. doi: 10.1055/s-0028-1091234. 
      Epub 2008 Sep 23.